Facebook
Twitter
Telegram
Report an ErrorTeva Pharmaceutical Industries Limited Balance Sheet 2011-2024 | TEVA
Annual Balance Sheet Teva Pharmaceutical Industries Limited
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-2.59 B | -2.1 B | -1.33 B | 21 B | 805 M | 27.1 B | 31.5 B | 34.8 B | 3.02 B | 8.1 B | 11.2 B | 11.8 B | 13.4 B |
Long Term Debt |
320 M | 349 M | 416 M | 22.7 B | 435 M | 26.7 B | 28.8 B | 32.5 B | 8.38 B | 8.57 B | 10.4 B | 11.7 B | 10.2 B |
Long Term Debt Current |
320 M | 349 M | 416 M | 479 M | 435 M | 1.7 B | 2.88 B | 810 M | 989 M | 1.18 B | 816 M | 2.43 B | 1.16 B |
Total Non Current Liabilities |
23.1 B | 23.9 B | 25.4 B | 26.4 B | 28.7 B | 30.6 B | 33.9 B | 39.4 B | 11.3 B | 10.8 B | 12.9 B | 14.9 B | 14 B |
Total Current Liabilities |
12.2 B | 11.5 B | 11 B | 13.2 B | 13.7 B | 14.3 B | 17.9 B | 18.5 B | 13 B | 12.3 B | 12 B | 12.9 B | 13.8 B |
Total Liabilities |
35.4 B | 35.4 B | 36.4 B | 39.6 B | 43.5 B | 46 B | 51.9 B | 57.9 B | 24.3 B | 23.1 B | 24.9 B | 27.7 B | 27.8 B |
Deferred Revenue |
- | - | - | - | 386 M | 368 M | - | - | - | - | - | - | - |
Retained Earnings |
-13.5 B | -13 B | -10.5 B | -10.9 B | -6.96 B | -5.96 B | -3.8 B | 13.6 B | 14.9 B | 14.4 B | 12.5 B | 12.3 B | 11.3 B |
Total Assets |
43.5 B | 44 B | 47.7 B | 50.6 B | 57.5 B | 60.7 B | 70.6 B | 92.9 B | 54.3 B | 46.4 B | 47.5 B | 50.6 B | 50.1 B |
Cash and Cash Equivalents |
3.23 B | 2.8 B | 2.16 B | 2.18 B | 1.98 B | 1.78 B | 963 M | 988 M | 6.95 B | 2.23 B | 1.04 B | 2.88 B | 1.1 B |
Book Value |
8.13 B | 8.6 B | 11.2 B | 11.1 B | 14 B | 14.7 B | 18.7 B | 35 B | 29.9 B | 23.4 B | 22.6 B | 22.9 B | 22.3 B |
Total Shareholders Equity |
7.51 B | 7.8 B | 11.2 B | 11.1 B | 14 B | 14.7 B | 17.4 B | 33.3 B | 29.8 B | 23.3 B | 22.6 B | 22.8 B | 22.2 B |
All numbers in USD currency
Quarterly Balance Sheet Teva Pharmaceutical Industries Limited
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
294 M | 324 M | 338 M | 345 M | 349 M | 354 M | - | 393 M | 416 M | 425 M | 444 M | 441 M | 479 M | 479 M | 479 M | 479 M | 435 M | 435 M | 435 M | 435 M | - | - | - | - | 28.8 B | 32 B | 33.8 B | 32.7 B | 32.5 B | 33.2 B | 8.04 B | 8.62 B | 8.36 B | - | - | - | 8.57 B | - | - | - | 11.2 B | - | - | - | 14.1 B | - | - | - | 11.4 B | - | - | - |
Total Non Current Liabilities |
21.4 B | 23.2 B | 23.5 B | 24.4 B | 23.8 B | 23.2 B | - | 25.2 B | 25.4 B | 24.6 B | 25.2 B | 25.9 B | 26.4 B | 26.4 B | 26.4 B | 26.4 B | 28.7 B | 28.7 B | 28.7 B | 28.7 B | 30.6 B | 30.6 B | 30.6 B | 30.6 B | 33.9 B | 33.9 B | 33.9 B | 33.9 B | 39.6 B | 42.4 B | 11.5 B | 11.6 B | 11.3 B | 12.7 B | 12.8 B | 11.8 B | 10.8 B | 11.3 B | 11.3 B | 12.5 B | 12.9 B | 13.3 B | 13.1 B | 12.9 B | 14.9 B | 15.9 B | 16 B | 13.6 B | 14.1 B | 6.86 B | 6.36 B | 7.24 B |
Total Liabilities |
35.2 B | 34.6 B | 35.4 B | 34.8 B | 35.3 B | 34.7 B | - | 36.8 B | 36.4 B | 36.4 B | 37.9 B | 38 B | 39.6 B | 39.6 B | 39.6 B | 39.6 B | 42.4 B | 42.4 B | 42.4 B | 42.4 B | 44.9 B | 44.9 B | 44.9 B | 44.9 B | 51.9 B | 51.9 B | 51.9 B | 51.9 B | 58.1 B | 61.7 B | 25.9 B | 24.5 B | 24.3 B | 25.7 B | 27.3 B | 24.3 B | 23.1 B | 22.9 B | 23.1 B | 23.9 B | 24.9 B | 25.5 B | 25.9 B | 25.3 B | 27.7 B | 26.5 B | 26 B | 27.3 B | 27.8 B | 18.3 B | 16.4 B | 16.1 B |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-13.7 B | -13.9 B | -14 B | -13.1 B | -12.9 B | -11.7 B | - | -11.5 B | -10.5 B | -10.4 B | -10.7 B | -10.9 B | -10.9 B | -10.9 B | -10.9 B | -10.9 B | -6.96 B | -6.96 B | -6.96 B | -6.96 B | -5.96 B | -5.96 B | -5.96 B | -5.96 B | -3.8 B | -3.81 B | -3.81 B | -3.81 B | 13.6 B | 15 B | 15 B | 15.1 B | 14.9 B | 14.7 B | 14.8 B | 14.6 B | 14.4 B | 14 B | 13.4 B | 13 B | 12.5 B | 12.4 B | 12 B | 12.7 B | 12.3 B | 12.2 B | 12.5 B | 11.9 B | 11.3 B | 11 B | 10.3 B | 9.88 B |
Total Assets |
42.8 B | 42.1 B | 43.1 B | 43.5 B | 44 B | 44.3 B | - | 47.1 B | 47.7 B | 47.9 B | 49.2 B | 49 B | 50.6 B | 50.6 B | 50.6 B | 50.6 B | 57.5 B | 57.5 B | 57.5 B | 57.5 B | 60.7 B | 60.7 B | 60.7 B | 60.7 B | 70.6 B | 70.6 B | 70.6 B | 70.6 B | 93.1 B | 98.7 B | 57.9 B | 55.1 B | 54.2 B | 48.6 B | 50.4 B | 47 B | 46.4 B | 46.6 B | 46.7 B | 46.9 B | 47.5 B | 47.8 B | 47.5 B | 48.1 B | 50.6 B | 49.6 B | 48.9 B | 50.5 B | 50.1 B | 41.3 B | 40.2 B | 39.3 B |
Cash and Cash Equivalents |
2.99 B | 2.25 B | 2.67 B | 2.14 B | 2.8 B | 2.22 B | 2.06 B | 2.18 B | 2.16 B | 2.04 B | 2.44 B | 1.74 B | 2.18 B | 2.18 B | 2.18 B | 2.18 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 1.78 B | 1.78 B | 1.78 B | 1.78 B | 963 M | 963 M | 963 M | 963 M | 988 M | 1.56 B | 6.98 B | 5.96 B | 6.95 B | 928 M | 1.07 B | 3.4 B | 2.23 B | 1.47 B | 949 M | 901 M | 1.04 B | 1.15 B | 1.24 B | 1.39 B | 2.88 B | 1.43 B | 1.19 B | 1.06 B | 1.1 B | 1.08 B | 1.14 B | 721 M |
Book Value |
7.54 B | 7.51 B | 7.71 B | 8.61 B | 8.69 B | 9.52 B | - | 10.3 B | 11.2 B | 11.5 B | 11.3 B | 11 B | 11.1 B | 11.1 B | 11.1 B | 11.1 B | 15.1 B | 15.1 B | 15.1 B | 15.1 B | 15.8 B | 15.8 B | 15.8 B | 15.8 B | 18.7 B | 18.7 B | 18.7 B | 18.7 B | 35 B | 37 B | 32 B | 30.6 B | 29.9 B | 22.9 B | 23.1 B | 22.7 B | 23.4 B | 23.7 B | 23.6 B | 23 B | 22.6 B | 22.4 B | 21.6 B | 22.8 B | 22.9 B | 23.1 B | 22.9 B | 23.2 B | 22.3 B | 22.9 B | 23.7 B | 23.1 B |
Total Shareholders Equity |
7.28 B | 6.93 B | 7.05 B | 8.5 B | 7.9 B | 9.52 B | 9.83 B | 10.3 B | 10.3 B | 11.5 B | 10.3 B | 10 B | 10 B | 10 B | 10 B | 10 B | 14 B | 14 B | 14 B | 14 B | 14.7 B | 14.7 B | 14.7 B | 14.7 B | 17.4 B | 17.4 B | 17.4 B | 17.4 B | 33.3 B | 35.1 B | 30.2 B | 30.4 B | 29.8 B | 22.7 B | 23 B | 22.6 B | 23.3 B | 23.6 B | 23.5 B | 23 B | 22.6 B | 22.3 B | 21.5 B | 22.7 B | 22.8 B | 22.9 B | 22.8 B | 23.1 B | 22.2 B | 22.9 B | 23.7 B | 23.1 B |
All numbers in USD currency